93993-37-4

Basic information

• Product Name: 1,1,4,4-tetramethyl-6-(propan-2-yl)-1,2,3,4-tetrahydronaphthalene
• CAS NO: 93993-37-4
• Molecular Formula: C₁₇H₂₆
• Molecular Weight: 230.3883
• Mol File: 93993-37-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 286.5°C at 760 mmHg
• Flash Point: 122.4°C
• Density: 0.875g/cm³
• Vapor Pressure: 0.00453mmHg at 25°C
• Refractive Index: 1.488
• CAS DataBase Reference: 1,1,4,4-tetramethyl-6-(propan-2-yl)-1,2,3,4-tetrahydronaphthalene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,4,4-tetramethyl-6-(propan-2-yl)-1,2,3,4-tetrahydronaphthalene(93993-37-4)
• EPA Substance Registry System: 1,1,4,4-tetramethyl-6-(propan-2-yl)-1,2,3,4-tetrahydronaphthalene(93993-37-4)

Safety Data

• Hazardous Substances Data: 93993-37-4(Hazardous Substances Data)

Usage

Physical state

Colorless, flammable liquid

Odor

Sweet, floral

Uses

a. Fragrance ingredient in perfumes, personal care products, and household cleaners
b. Solvent in the production of industrial products such as adhesives and coatings
c. Starting material for the synthesis of various drugs and pharmaceutical compounds

Toxicity

Low toxicity

Health and environmental concerns

Not known to cause significant health or environmental concerns

Upstream product

• 110-03-2 2,5-dimethyl-2,5-hexanediol 
• 98-82-8 Isopropylbenzene 
• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 

Downstream Products

• 158499-07-1 methyl 4-<1-(3-isopropyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl>benzoate 
• 158499-15-1 methyl 4-<(3-isopropyl-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)carbonyl>benzoate 
• 94003-18-6 1.1.4.4-Trimethyl-6-isopropyl-7-formyl-tetralin 

Relevant articles and documents

COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES

Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.